Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Pleyer, L; Germing, U; Sperr, WR; Linkesch, W; Burgstaller, S; Stauder, R; Girschikofsky, M; Schreder, M; Pfeilstocker, M; Lang, A; Sliwa, T; Geissler, D; Schlick, K; Placher-Sorko, G; Theiler, G; Thaler, J; Mitrovic, M; Neureiter, D; Valent, P; Greil, R.
Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival.
Leuk Res. 2014; 38(4):475-483 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Linkesch Werner
Theiler Georg

Dimensions Citations:

Plum Analytics:
Recent data suggest that azacitidine may be beneficial in CMML. We report on 48 CMML-patients treated with azacitidine. Overall response rates were high (70% according to IWG-criteria, including 22% complete responses). Monocyte count and cytogenetics adversely affected survival, whereas age, WHO-type, FAB-type, and spleen size did not. Matched-pair analyses revealed a trend for higher two-year-survival for azacitidine as compared to best supportive care (62% vs. 41%, p=0.067) and longer OS for azacitidine first-line vs. hydroxyurea first-line (p=0.072, median OS 27.7 vs. 6.2 months). This report reinforces existing evidence that azacitidine is safe and efficacious in both myelodysplastic and myeloproliferative CMML. Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Activities of Daily Living -
Adult -
Aged -
Aged, 80 and over -
Antimetabolites, Antineoplastic - therapeutic use
Azacitidine - therapeutic use
Disease Progression -
Female -
Humans -
Leukemia, Myelomonocytic, Chronic - drug therapy
Leukemia, Myelomonocytic, Chronic - mortality
Male -
Matched-Pair Analysis -
Middle Aged -
Survival Analysis -

Find related publications in this database (Keywords)
Matched-pair analysis
Chronic myelomonocytic leukemia
Austrian Azacitidine Registry
© Meduni Graz Impressum